Eric Topol

And if there's any questions before we wrap up, this is a good time to put them in the message.

Somebody did ask about colchicine.

Like, for example, if you have atherosclerosis,

and you had inflammation and you're denoting artery inflammation, would you be able to see whether the medications are bringing down the inflammation?

You would agree that's probably a good way to gauge the ability to suppress inflammation?

Yeah, no, I think you probably could pick up what's going on in the arteries without even, you know, just from the sensor you had already put in the animal model and see whether you're suppressing inflammation.

Another person asked about long COVID, and that's really intriguing because here you have dysregulated immune system.

You have often high levels of inflammation.

And then we don't have a treatment.

So this might be a really good way, a validated treatment, to see whether or not you're making progress in long COVID.

We don't even have a biomarker, but it could be your sensor is a way to really light that area up.

Don't you think?

All right.

Well, we touched on a few of the questions, which are really good ones.

I also want to just say, I've gotten a glimpse to the future here, folks.

Those of you who are here with us live or listening or watching the archives,

The reason is because this is giving us a new opportunity for individualizing and promoting the health of an individual.

So it's really pretty extraordinary.

You may not know it today, and you may start seeing results in people in 2027.

but what you started here is just so extraordinary.